- Home
- ADV vs ETNB Comparison
ADV vs ETNB Comparison
Compare ADV & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- ETNB
- Stock Information
- Founded
- ADV 1987
- ETNB 2018
- Country
- ADV United States
- ETNB United States
- Employees
- ADV N/A
- ETNB N/A
- Industry
- ADV Business Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- ETNB Health Care
- Exchange
- ADV Nasdaq
- ETNB Nasdaq
- Market Cap
- ADV 875.7M
- ETNB 1.0B
- IPO Year
- ADV N/A
- ETNB 2019
- Fundamental
- Price
- ADV $1.22
- ETNB $6.06
- Analyst Decision
- ADV Strong Buy
- ETNB Strong Buy
- Analyst Count
- ADV 1
- ETNB 10
- Target Price
- ADV $3.50
- ETNB $27.56
- AVG Volume (30 Days)
- ADV 682.7K
- ETNB 2.5M
- Earning Date
- ADV 05-08-2025
- ETNB 05-08-2025
- Dividend Yield
- ADV N/A
- ETNB N/A
- EPS Growth
- ADV N/A
- ETNB N/A
- EPS
- ADV N/A
- ETNB N/A
- Revenue
- ADV $3,566,324,000.00
- ETNB N/A
- Revenue This Year
- ADV N/A
- ETNB N/A
- Revenue Next Year
- ADV N/A
- ETNB N/A
- P/E Ratio
- ADV N/A
- ETNB N/A
- Revenue Growth
- ADV N/A
- ETNB N/A
- 52 Week Low
- ADV $1.11
- ETNB $4.16
- 52 Week High
- ADV $4.82
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- ADV 34.89
- ETNB 42.57
- Support Level
- ADV $1.18
- ETNB $5.68
- Resistance Level
- ADV $1.28
- ETNB $6.13
- Average True Range (ATR)
- ADV 0.12
- ETNB 0.69
- MACD
- ADV 0.02
- ETNB 0.03
- Stochastic Oscillator
- ADV 26.83
- ETNB 51.62
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is the provider of outsourced sales and marketing solutions to consumer goods companies and retailers. It has a technology-enabled platform of sales and marketing services like headquarter sales, retail merchandising, in-store sampling, digital commerce, and shopper marketing. For brands and retailers of all sizes, the firm helps to get the right products on the shelf and into the hands of consumers. The company helps its clients to sell more while spending less. Advantage has offices throughout North America and strategic investments in select markets throughout Africa, Asia, Australia, and Europe through which it services the global needs of multinational, regional, and local manufacturers. Its services are provided across two segments sales and marketing.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).